You just read:

Eisai Initiates Phase II Study of Dual Orexin Receptor Antagonist Lemborexant in People with Irregular Sleep-Wake Rhythm Disorder (ISWRD) and Dementia

News provided by

Eisai

08 Nov, 2016, 00:01 GMT